

Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2022 [Japanese GAAP]

August 8, 2022

Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd. Securities code:

3902 URL https://www.mdv.co.jp/

Representative: (Title) President

Inquiries: (Title) Executive Officer and General Manager of (Name) Masahiro Kihara Tel: +81-3-5283-6911

Corporate Planning Division

Scheduled date to file quarterly report: August 9, 2022

Scheduled date to commence dividend payments:

Preparation of supplementary material on quarterly financial results: Yes

Holding of quarterly financial results briefing : Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted)

(Name) Hiroyuki Iwasaki

1. Consolidated financial results for the second quarter of the fiscal year ending December 31, 2022 (from January 1, 2022 to June 30, 2022) (Percentages indicate year-on-year changes)

(1) Consolidated operating results (cumulative)

(1) Consolidated operating re	(1	creentages inc	iicaic yeai-oii-	year changes)				
	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Second quarter of FY ending December 31, 2022 Second quarter of FY ended	2,856	-	785	-	776	-	522	-
December 31, 2021	2,635	28.8	720	51.4	719	50.8	484	51.7

(Note) Comprehensive income Second quarter of fiscal year ending December 31, 2022 522 million yen [-%] Second quarter of fiscal year ended December 31, 2021 499 million yen [56.3%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Second quarter of FY		
ending December 31, 2022	13.65	13.64
Second quarter of FY ended		
December 31, 2021	12.32	-

⁽Note) 1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. Consolidated earnings for the 2nd quarter of the fiscal year ending December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

(2) Consolidated financial position

(2) COMBONIAMICA INMANIANI	F			
	Total assets	Net assets	Equity-to-asset ratio	
	Millions of yen	Millions of yen	%	
As of June30, 2022				
(2Q FY2022)	4,675	3,279	68.2	
As of December 31, 2021				
(FY2021)	5,534	4,205	75.1	

(Reference) Equity As of June 30, 2022 3,186 million yen As of December 31, 2021 4,156 million yen

Cash dividends

2. Cash dividends								
	Annual dividends per share							
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen			
FY ended								
December 31, 2021	-	0.00	-	5.60	5.60			
FY ending								
December 31, 2022	-	0.00						
FY ending								
December 31, 2022								
(forecast)			-	6.00	6.00			

(Note) Revision of the latest released dividend forecast

^{2.} Diluted earnings per share for the six months ended June 30, 2021 are not presented as there are no potential shares.

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2022 (from January 1, 2022 to December 31, 2022)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	6,300	-	1,599	-	1,600	-	1,098	-	28.74

(Notes) 1. Revision of the latest released earnings forecasts : None

- 2. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. The above consolidated earnings forecasts therefore are the amount after applying such accounting standard and related implementation guidance, presenting no year-on-year changes.
- 3. The Company purchased 763,400 treasury shares from January 1, 2022 to January 25, 2022 based on the resolution of the Board of Directors held on December 22, 2021. Basic earnings per share for the consolidated earnings forecasts takes into account the impact of the purchase of treasury shares.

* Notes

(1) Changes in significant subsidiaries during the three months ended March 31, 2022 (changes in specified subsidiaries resulting in changes in scope of consolidation) : None

Newly included: - companies (Company name)

, Excluded: - companies (Company name)

(2) Application of special accounting treatment to the preparation of quarterly consolidated financial statements : None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies other than (i) above : None

(iii) Changes in accounting estimates : None (iv) Restatement : None

(Notes) For more details, please refer to "(4) Notes to quarterly consolidated financial statements (Change in accounting policies) in 2. Quarterly consolidated financial statements and Key notes" on page 5 of the attached materials.

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

(ii) Number of treasury shares at the end of the period

(iii) Average number of shares outstanding during the period (cumulative quarterly period)

As of June 30, 2022	40,027,526 shares	As of December 31, 2021	40,027,526 shares
As of June 30, 2022	1,830,678 shares	As of December 31, 2021	1,067,278 shares
Second quarter of FY		Second quarter fiscal	
ending December 31,	38,272,311 shares	year ended December	39,299,332 shares
2022		31, 2021	

^{*} Quarterly financial results reports are exempt from a quarterly review conducted by certified public accountants or an audit corporation.

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.

^{*} Proper use of earnings forecasts, and other special matters